Market Snapshot

BSE Sensex: 81287.19 -1.17%
BSE 500: 36322.56 -1.16%
BSE 200: 11486.28 -1.19%
BSE 100: 26446.46 -1.22%
BSE BANKEX: 68139.54 -1.01%
BSE IT: 29754.94 0.27%
Nifty 50: 25178.65 -1.25%
Nifty 500: 23166.85 -1.20%
Nifty 200: 14121.05 -1.23%
Nifty 100: 25897.55 -1.26%
Nifty Midcap 100: 59115.6 -1.14%
Nifty Small 100: 16928.9 -1.10%
Nifty IT: 30603.85 0.16%
Nifty PSU Bank: 9820.45 -0.60%

News:

GPT Infra acquires 100% stake ...
Microfinance stocks slide afte...
Home First Finance Company Ind...
Renaissance Global Ltd leads l...
Mastek?s UK arm bags 5-year $6...

Caplin Point Laboratories Ltd Share Price – NSE / BSE
Pharmaceuticals, Small Cap

Invest

27 Feb 2026 | 04:14 PM

1,700.10

-28.50 (-1.65%)

Add to Watchlist

This awesome feature is still in our labs.
Set Alert

This awesome feature is still in our labs.

Underperforms Index

-11.55%

Return (1Y)

Underperformed Nifty 500 by 25.59%
More Volatile

2.3%

Standard Deviation (1Y)

Higher than Nifty 500 by 1.48%
Not so consistent

5/12

Months

underperformed Nifty 500
AxisDirect View

No View

52 Week High-Low

2,395

1,599

News & Announcements

Caplin Point?s arm Caplin Steriles gets USFDA nod for Sodium Phosphates Injection
4 days ago

Caplin Point?s arm Caplin Steriles gets USFDA nod for Sodium Phosphates Injection

24 - Feb - 2026 12:00 | 4 days ago

The approval covers Sodium Phosphates Injection USP in strengths of 15mM P/5mL, 45mM P/15mL and 150mM P/50mL (3mM P/mL) single-dose vials. The product is a generic therapeutic equivalent of the Reference Listed Drug (RLD), approved under NDA 018892 and marketed by Hospira, Inc., USA.
Sodium Phosphates Injection is indicated as a source of phosphorus for addition to large volume intravenous fluids to prevent or treat hypophosphatemia in patients with limited or no oral intake. It is also used in the preparation of customised parenteral nutrition formulations when standard electrolyte or nutrient solutions are inadequate to meet patient requirements.
According to IQVIA (IMS Health) data, the approved strengths of Sodium Phosphates Injection recorded total US sales of approximately $67 million for the 12-month period ended December 2025.
Caplin Point Laboratories is a pharmaceutical company with a unique business model catering predominantly to emerging markets of Latin America and Africa. The company also has a growing presence in the regulated markets such as US through its subsidiary Caplin Steriles and Caplin Steriles USA Inc.
The company's consolidated net profit rose 17.9% to Rs 163.88 crore while net sales increase 10.1% to Rs 542.77 crore in Q3 FY26 over Q3 FY25.
The counter declined 1.49% to Rs 1,706.90 on the BSE.
Powered by Capital Market - Live News
Caplin Point Laboratories consolidated net profit rises 17.93% in the December 2025 quarter
23 days ago

Caplin Point Laboratories consolidated net profit rises 17.93% in the December 2025 quarter

05 - Feb - 2026 12:00 | 23 days ago

Net profit of Caplin Point Laboratories rose 17.93% to Rs 163.88 crore in the quarter ended December 2025 as against Rs 138.96 crore during the previous quarter ended December 2024. Sales rose 10.10% to Rs 542.77 crore in the quarter ended December 2025 as against Rs 492.96 crore during the previous quarter ended December 2024.

Particulars Quarter Ended
Dec. 2025 Dec. 2024 % Var.

Sales 542.77 492.96 10

OPM % 34.94 32.92 -

PBDT 223.17 193.46 15

PBT 203.89 177.26 15

NP 163.88 138.96 18

Powered by Capital Market - Live News
Caplin Point Laboratories to announce Quarterly Result
32 days ago

Caplin Point Laboratories to announce Quarterly Result

27 - Jan - 2026 12:00 | 32 days ago

Caplin Point Laboratories will hold a meeting of the Board of Directors of the Company on 5 February 2026.
Powered by Capital Market - Live News
Caplin Point Laboratories consolidated net profit rises 18.08% in the September 2025 quarter
115 days ago

Caplin Point Laboratories consolidated net profit rises 18.08% in the September 2025 quarter

05 - Nov - 2025 12:00 | 115 days ago

Net profit of Caplin Point Laboratories rose 18.08% to Rs 154.45 crore in the quarter ended September 2025 as against Rs 130.80 crore during the previous quarter ended September 2024. Sales rose 10.54% to Rs 534.04 crore in the quarter ended September 2025 as against Rs 483.10 crore during the previous quarter ended September 2024.

Particulars Quarter Ended
Sep. 2025 Sep. 2024 % Var.

Sales 534.04 483.10 11

OPM % 35.42 34.08 -

PBDT 219.40 185.22 18

PBT 201.00 168.46 19

NP 154.45 130.80 18

Powered by Capital Market - Live News

Price vs Volume

Stock Trivia

Caplin Point Laboratories Ltd is trading very close to its 52 Week Low
MF shareholding in Caplin Point Laboratories Ltd has increased by 10.04% since past 3 Months
FII shareholding in Caplin Point Laboratories Ltd has increased by 34.83% since past 1 Year
MF shareholding in Caplin Point Laboratories Ltd has increased by 5.96% since past 1 Year

Peer Comparison on Risk - Return

Thanks for Liking, Please spread your love by sharing...

Particulars	Quarter Ended
	Dec. 2025	Dec. 2024	% Var.
Sales	542.77	492.96	10
OPM %	34.94	32.92	-
PBDT	223.17	193.46	15
PBT	203.89	177.26	15
NP	163.88	138.96	18

Particulars	Quarter Ended
	Sep. 2025	Sep. 2024	% Var.
Sales	534.04	483.10	11
OPM %	35.42	34.08	-
PBDT	219.40	185.22	18
PBT	201.00	168.46	19
NP	154.45	130.80	18

General Notifications

My Notifications

Research Notifications

Caplin Point Laboratories Ltd Share Price – NSE / BSE Pharmaceuticals, Small Cap

1,700.10 -28.50 (-1.65%)

News & Announcements

Price vs Volume

Stock Trivia

Caplin Point Laboratories Ltd Share Price – NSE / BSE
Pharmaceuticals, Small Cap

1,700.10

-28.50 (-1.65%)